{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T18:27:38Z","timestamp":1772821658253,"version":"3.50.1"},"reference-count":15,"publisher":"Oxford University Press (OUP)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,6,1]]},"DOI":"10.1093\/infdis\/jis269","type":"journal-article","created":{"date-parts":[[2012,4,4]],"date-time":"2012-04-04T00:43:30Z","timestamp":1333500210000},"page":"1705-1708","source":"Crossref","is-referenced-by-count":53,"title":["Risk of Tuberculosis Reactivation With Tofacitinib (CP-690550)"],"prefix":"10.1093","volume":"205","author":[{"given":"Mamoudou","family":"Maiga","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shichun","family":"Lun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haidan","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathryn","family":"Winglee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole C.","family":"Ammerman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William R.","family":"Bishai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2012,4,3]]},"reference":[{"key":"key\n\t\t\t\t20170702144543_JIS269C1","volume-title":"Global tuberculosis control 2010","author":"World Health Organization","year":"2010"},{"key":"key\n\t\t\t\t20170702144543_JIS269C2","doi-asserted-by":"crossref","first-page":"15","DOI":"10.4049\/jimmunol.0903856","article-title":"Understanding latent tuberculosis: a moving target","volume":"185","author":"Lin","year":"2010","journal-title":"J Immunol"},{"key":"key\n\t\t\t\t20170702144543_JIS269C3","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa011110","article-title":"Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent","volume":"345","author":"Keane","year":"2001","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170702144543_JIS269C4","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1365-2036.2007.03553.x","article-title":"Review article: minimizing tuberculosis during anti-tumour necrosis factor-alpha treatment of inflammatory bowel disease","volume":"27","author":"Theis","year":"2008","journal-title":"Aliment Pharmacol Ther"},{"key":"key\n\t\t\t\t20170702144543_JIS269C5","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1002\/art.24567","article-title":"The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo","volume":"60","author":"Kremer","year":"2009","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t20170702144543_JIS269C6","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1111\/j.1600-6143.2008.02307.x","article-title":"Phase 1 dose-escalation study of CP-690 550 in stable renal allograft recipients: preliminary findings of safety, tolerability, effects on lymphocyte subsets and pharmacokinetics","volume":"8","author":"van Gurp","year":"2008","journal-title":"Am J Transplant"},{"key":"key\n\t\t\t\t20170702144543_JIS269C7","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1038\/jid.2009.25","article-title":"Double-blind, placebo-controlled, dose-escalation study to evaluate the pharmacologic effect of CP-690,550 in patients with psoriasis","volume":"129","author":"Boy","year":"2009","journal-title":"J Invest Dermatol"},{"key":"key\n\t\t\t\t20170702144543_JIS269C8","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1164\/rccm.200905-0795OC","article-title":"Short-course therapy with daily rifapentine in a murine model of latent tuberculosis infection","volume":"180","author":"Zhang","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"key\n\t\t\t\t20170702144543_JIS269C9","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1128\/IAI.72.2.1065-1071.2004","article-title":"Paucibacillary tuberculosis in mice after prior aerosol immunization with Mycobacterium bovis BCG","volume":"72","author":"Nuermberger","year":"2004","journal-title":"Infect Immun"},{"key":"key\n\t\t\t\t20170702144543_JIS269C10","first-page":"414","article-title":"The effect of CP-690,550, a Janus kinase inhibitor, on QTC interval and blood pressure: a concentration-response analysis of phase I data","volume":"86","author":"Krishnaswami","year":"2008","journal-title":"Transplantation"},{"key":"key\n\t\t\t\t20170702144543_JIS269C11","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.ejphar.2007.12.024","article-title":"The JAK-3 inhibitor CP-690550 is a potent anti-inflammatory agent in a murine model of pulmonary eosinophilia","volume":"582","author":"Kudlacz","year":"2008","journal-title":"Eur J Pharmacol"},{"key":"key\n\t\t\t\t20170702144543_JIS269C12"},{"key":"key\n\t\t\t\t20170702144543_JIS269C13","doi-asserted-by":"crossref","first-page":"4234","DOI":"10.4049\/jimmunol.1003668","article-title":"Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550)","volume":"186","author":"Ghoreschi","year":"2011","journal-title":"J Immunol"},{"key":"key\n\t\t\t\t20170702144543_JIS269C14","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/j.1462-5822.2009.01424.x","article-title":"Penitentiary or penthouse condo: the tuberculous granuloma from the microbe's point of view","volume":"12","author":"Paige","year":"2010","journal-title":"Cell Microbiol"},{"key":"key\n\t\t\t\t20170702144543_JIS269C15","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1093\/ajhp\/57.3.225","article-title":"New drugs for the treatment of rheumatoid arthritis","volume":"57","author":"Schuna","year":"2000","journal-title":"Am J Health Syst Pharm"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jid\/article-pdf\/205\/11\/1705\/18066644\/jis269.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,26]],"date-time":"2019-06-26T20:21:31Z","timestamp":1561580491000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article-lookup\/doi\/10.1093\/infdis\/jis269"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4,3]]},"references-count":15,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2012,4,3]]},"published-print":{"date-parts":[[2012,6,1]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jis269","relation":{},"ISSN":["1537-6613","0022-1899"],"issn-type":[{"value":"1537-6613","type":"electronic"},{"value":"0022-1899","type":"print"}],"subject":[],"published":{"date-parts":[[2012,4,3]]}}}